ReShape Lifesciences Q3 FY23: revenue $2.2M; diluted EPS −$87,209.30

Key figures from this report

These are the numbers ReShape Lifesciences reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$2.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
2. Net income−$3.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
3. Diluted EPS−$87,209.30No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$1.0210-Q income statement, on EDGAR
4. Cash and cash equivalents$1.4MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
5. Cash from operations−$2.8MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables